-
2
-
-
32944456100
-
Metformin monotherapy for type 2 diabetes mellitus
-
CD002966
-
Saenz A, Fernandez-Esteban I, Mataix A, Ausejo M, Roque M, Moher D. Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database Syst. Rev., CD002966 (2005).
-
(2005)
Cochrane Database Syst. Rev.
-
-
Saenz, A.1
Fernandez-Esteban, I.2
Mataix, A.3
Ausejo, M.4
Roque, M.5
Moher, D.6
-
3
-
-
60449089649
-
Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes
-
American Diabetes Association European Association for Study of Diabetes
-
Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B, American Diabetes Association European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 32, 193-203 (2009).
-
(2009)
Diabetes Care
, vol.32
, pp. 193-203
-
-
Nathan, D.M.1
Buse, J.B.2
Davidson, M.B.3
Ferrannini, E.4
Holman, R.R.5
Sherwin, R.6
Zinman, B.7
-
4
-
-
79958197888
-
Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: A nationwide study
-
Schramm TK, Gislason GH, Vaag A, Rasmussen JN, Folke F, Hansen ML, Fosbøl EL, Køber L, Norgaard ML, Madsen M, Hansen PR, Torp-Pedersen C. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur. Heart J., 32, 1900-1908 (2011).
-
(2011)
Eur. Heart J.
, vol.32
, pp. 1900-1908
-
-
Schramm, T.K.1
Gislason, G.H.2
Vaag, A.3
Rasmussen, J.N.4
Folke, F.5
Hansen, M.L.6
Fosbøl, E.L.7
Køber, L.8
Norgaard, M.L.9
Madsen, M.10
Hansen, P.R.11
Torp-Pedersen, C.12
-
5
-
-
0037034257
-
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
-
Diabetes Prevention Program Research Group
-
Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM, Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med., 346, 393-403 (2002).
-
(2002)
N. Engl. J. Med.
, vol.346
, pp. 393-403
-
-
Knowler, W.C.1
Barrett-Connor, E.2
Fowler, S.E.3
Hamman, R.F.4
Lachin, J.M.5
Walker, E.A.6
Nathan, D.M.7
-
6
-
-
17144389303
-
The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: The Diabetes Prevention Program randomized trial
-
Diabetes Prevention Program Research Group
-
Orchard TJ, Temprosa M, Goldberg R, Haffner S, Ratner R, Marcovina S, Fowler S, Diabetes Prevention Program Research Group. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann. Intern. Med., 142, 611-619 (2005).
-
(2005)
Ann. Intern. Med.
, vol.142
, pp. 611-619
-
-
Orchard, T.J.1
Temprosa, M.2
Goldberg, R.3
Haffner, S.4
Ratner, R.5
Marcovina, S.6
Fowler, S.7
-
7
-
-
80052838160
-
A systematic review of metformin to limit weight-gain with atypical antipsychotics
-
Lee YJ, Jeong JH. A systematic review of metformin to limit weight-gain with atypical antipsychotics. J. Clin. Pharm. Ther., 36, 537-545 (2011).
-
(2011)
J. Clin. Pharm. Ther.
, vol.36
, pp. 537-545
-
-
Lee, Y.J.1
Jeong, J.H.2
-
8
-
-
0031472452
-
Efficacy of metformin in type II diabetes: Results of a double-blind, placebo-controlled, dose-response trial
-
Garber AJ, Duncan TG, Goodman AM, Mills DJ, Rohlf JL. Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am. J. Med., 103, 491-497 (1997).
-
(1997)
Am. J. Med.
, vol.103
, pp. 491-497
-
-
Garber, A.J.1
Duncan, T.G.2
Goodman, A.M.3
Mills, D.J.4
Rohlf, J.L.5
-
9
-
-
23944491714
-
Safety and tolerability of pioglitazone, metformin, and gliclazide in the treatment of type 2 diabetes
-
Belcher G, Lambert C, Edwards G, Urquhart R, Matthews DR. Safety and tolerability of pioglitazone, metformin, and gliclazide in the treatment of type 2 diabetes. Diabetes Res. Clin. Pract., 70, 53-62 (2005).
-
(2005)
Diabetes Res. Clin. Pract.
, vol.70
, pp. 53-62
-
-
Belcher, G.1
Lambert, C.2
Edwards, G.3
Urquhart, R.4
Matthews, D.R.5
-
11
-
-
81355132695
-
Evaluation of chronic diarrhea
-
Juckett G, Trivedi R. Evaluation of chronic diarrhea. Am. Fam. Physician, 84, 1119-1126 (2011).
-
(2011)
Am. Fam. Physician
, vol.84
, pp. 1119-1126
-
-
Juckett, G.1
Trivedi, R.2
-
12
-
-
0036113940
-
Guideline for the management of acute diarrhea in adults
-
Working Party of the Program Committ of the Bangkok World Congress of Gastroenterology 2002
-
Manatsathit S, Dupont HL, Farthing M, Kositchaiwat C, Leelakusolvong S, Ramakrishna BS, Sabra A, Speelman P, Surangsrirat S, Working Party of the Program Committ of the Bangkok World Congress of Gastroenterology 2002. Guideline for the management of acute diarrhea in adults. J. Gastroenterol. Hepatol., 17 (Suppl.), S54-S71 (2002).
-
(2002)
J. Gastroenterol. Hepatol.
, vol.17
, Issue.SUPPL.
-
-
Manatsathit, S.1
Dupont, H.L.2
Farthing, M.3
Kositchaiwat, C.4
Leelakusolvong, S.5
Ramakrishna, B.S.6
Sabra, A.7
Speelman, P.8
Surangsrirat, S.9
-
13
-
-
17044458998
-
Guidelines for the investigation of chronic diarrhoea
-
2nd edition
-
Thomas PD, Forbes A, Green J, Howdle P, Long R, Playford R, Sheridan M, Stevens R, Valori R, Walters J, Addison GM, Hill P, Brydon G. Guidelines for the investigation of chronic diarrhoea, 2nd edition. Gut, 52 (Suppl. 5), v1-v15 (2003).
-
(2003)
Gut
, vol.52
, Issue.SUPPL. 5
-
-
Thomas, P.D.1
Forbes, A.2
Green, J.3
Howdle, P.4
Long, R.5
Playford, R.6
Sheridan, M.7
Stevens, R.8
Valori, R.9
Walters, J.10
Addison, G.M.11
Hill, P.12
Brydon, G.13
-
15
-
-
0016916438
-
Prediction of creatinine clearance from serum creatinine
-
Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron, 16, 31-41 (1976).
-
(1976)
Nephron
, vol.16
, pp. 31-41
-
-
Cockcroft, D.W.1
Gault, M.H.2
-
16
-
-
79955779150
-
-
Rockville MD, Agency for Healthcare Research and Quality, U.S., March
-
Bennett WL, Wilson LM, Bolen S, Maruthur N, Singh S, Chatterjee R, Marinopoulos SS, Puhan MA, Ranasinghe P, Nicholson WK, Block L, Odelola O, Dalal DS, Ogbeche GE, Chandrasekhar A, Hutfless S, Bass EB, Segal JB. "Oral Diabetes Medications for Adults With Type 2 Diabetes: An Update.": 〈http://www.ncbi.nlm.nih.gov/books/NBK55754〉, Rockville MD, Agency for Healthcare Research and Quality, U.S., March, 2011.
-
(2011)
Oral Diabetes Medications for Adults with Type 2 Diabetes: An Update
-
-
Bennett, W.L.1
Wilson, L.M.2
Bolen, S.3
Maruthur, N.4
Singh, S.5
Chatterjee, R.6
Marinopoulos, S.S.7
Puhan, M.A.8
Ranasinghe, P.9
Nicholson, W.K.10
Block, L.11
Odelola, O.12
Dalal, D.S.13
Ogbeche, G.E.14
Chandrasekhar, A.15
Hutfless, S.16
Bass, E.B.17
Segal, J.B.18
-
17
-
-
33845405222
-
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
-
ADOPT Study Group
-
Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G, ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N. Engl. J. Med., 355, 2427-2443 (2006).
-
(2006)
N. Engl. J. Med.
, vol.355
, pp. 2427-2443
-
-
Kahn, S.E.1
Haffner, S.M.2
Heise, M.A.3
Herman, W.H.4
Holman, R.R.5
Jones, N.P.6
Kravitz, B.G.7
Lachin, J.M.8
O'Neill, M.C.9
Zinman, B.10
Viberti, G.11
-
19
-
-
70350075408
-
Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver
-
Nies AT, Koepsell H, Winter S, Burk O, Klein K, Kerb R, Zanger UM, Keppler D, Schwab M, Schaeffeler E. Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver. Hepatology, 50, 1227-1240 (2009).
-
(2009)
Hepatology
, vol.50
, pp. 1227-1240
-
-
Nies, A.T.1
Koepsell, H.2
Winter, S.3
Burk, O.4
Klein, K.5
Kerb, R.6
Zanger, U.M.7
Keppler, D.8
Schwab, M.9
Schaeffeler, E.10
-
21
-
-
0017653672
-
Alteration of bile acid metabolism and vitamin-B12-absorption in diabetics on biguanides
-
Caspary WF, Zavada I, Reimold W, Deuticke U, Emrich D, Willms B. Alteration of bile acid metabolism and vitamin-B12-absorption in diabetics on biguanides. Diabetologia, 13, 187-193 (1977).
-
(1977)
Diabetologia
, vol.13
, pp. 187-193
-
-
Caspary, W.F.1
Zavada, I.2
Reimold, W.3
Deuticke, U.4
Emrich, D.5
Willms, B.6
-
22
-
-
0031847175
-
Effect of metformin on bile salt circulation and intestinal motility in type 2 diabetes mellitus
-
Scarpello JH, Hodgson E, Howlett HC. Effect of metformin on bile salt circulation and intestinal motility in type 2 diabetes mellitus. Diabet. Med., 15, 651-656 (1998).
-
(1998)
Diabet. Med.
, vol.15
, pp. 651-656
-
-
Scarpello, J.H.1
Hodgson, E.2
Howlett, H.C.3
-
23
-
-
78649908592
-
Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus
-
Cuthbertson J, Patterson S, O'Harte FP, Bell PM. Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus. Metabolism, 60, 52-56 (2011).
-
(2011)
Metabolism
, vol.60
, pp. 52-56
-
-
Cuthbertson, J.1
Patterson, S.2
O'Harte, F.P.3
Bell, P.M.4
-
24
-
-
77955573674
-
Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): A randomised trial
-
DURATION-2 Study Group
-
Bergenstal RM, Wysham C, Macconell L, Malloy J, Walsh B, Yan P, Wilhelm K, Malone J, Porter LE, DURATION-2 Study Group. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet, 376, 431-439 (2010).
-
(2010)
Lancet
, vol.376
, pp. 431-439
-
-
Bergenstal, R.M.1
Wysham, C.2
Macconell, L.3
Malloy, J.4
Walsh, B.5
Yan, P.6
Wilhelm, K.7
Malone, J.8
Porter, L.E.9
-
25
-
-
33846006173
-
The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
-
Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet, 368, 1696-1705 (2006).
-
(2006)
Lancet
, vol.368
, pp. 1696-1705
-
-
Drucker, D.J.1
Nauck, M.A.2
-
26
-
-
0030443768
-
Pharmacokinetics and pharmacodynamics of metformin in healthy subjects and patients with noninsulin-dependent diabetes mellitus
-
Sambol NC, Chiang J, O'Conner M, Liu CY, Lin ET, Goodman AM, Benet LZ, Karam JH. Pharmacokinetics and pharmacodynamics of metformin in healthy subjects and patients with noninsulin-dependent diabetes mellitus. J. Clin. Pharmacol., 36, 1012-1021 (1996).
-
(1996)
J. Clin. Pharmacol.
, vol.36
, pp. 1012-1021
-
-
Sambol, N.C.1
Chiang, J.2
O'Conner, M.3
Liu, C.Y.4
Lin, E.T.5
Goodman, A.M.6
Benet, L.Z.7
Karam, J.H.8
|